Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
Eledon will be showcasing updated long-term results from the Phase 2 BESTOW trial of Tegoprubart at the upcoming ATC conference. The trial focuses on leveraging Tegoprubart to prevent rejection in kidney transplant patients. The data to be presented includes significant improvements in rejection rates, with a notable reduction of 30% compared to current standard treatments. This landmark research highlights the potential of Tegoprubart as a promising option in the field of transplant medicine.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments